Castle Biosciences, Inc. Common Stock (CSTL) Stock
Key stats
- Market cap
- $1.05B
- Price / Earnings ratio
- -46.1x
- EPS (TTM)
- -$0.76
- Volume
- Loading
- 52-week high
- $44.28
- 52-week low
- $17.72
Source: third-party data provider, as of November 13, 2026
Compare with CSTL
Recent news

Castle Biosciences, Inc. (CSTL) Is Up 15.46% in One Week: What You Should Know
Castle Biosciences, Inc. (CSTL) Is Up 15.46% in One Week: What You Should Know
CSTL

Does Castle Biosciences (CSTL) Have the Potential to Rally 31.46% as Wall Street Analysts Expect?
Does Castle Biosciences (CSTL) Have the Potential to Rally 31.46% as Wall Street Analysts Expect?
CSTL

Castle Biosciences Raises Outlook as Melanoma, TissueCypher Tests Gain Traction
Castle Biosciences Raises Outlook as Melanoma, TissueCypher Tests Gain Traction
CSTL

Castle Biosciences, Inc. (CSTL) Reports Q2 Loss, Tops Revenue Estimates
Castle Biosciences, Inc. (CSTL) Reports Q2 Loss, Tops Revenue Estimates
CSTL
Technical indicators
- RSI 14
- 48.53
- MACD 12/26/9
- 0.10
- EMA 9 of MACD
- 0.25
- MACD histogram
- -0.16
- SMA 50
- $34.30
- Price below SMA 50
- EMA 50
- $33.64
- Price above EMA 50
- SMA 200
- $28.24
- Price above SMA 200
- EMA 200
- $31.39
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 3 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news

Castle Biosciences, Inc. (CSTL) Is Up 15.46% in One Week: What You Should Know
Castle Biosciences, Inc. (CSTL) Is Up 15.46% in One Week: What You Should Know
CSTL

Does Castle Biosciences (CSTL) Have the Potential to Rally 31.46% as Wall Street Analysts Expect?
Does Castle Biosciences (CSTL) Have the Potential to Rally 31.46% as Wall Street Analysts Expect?
CSTL

Castle Biosciences Raises Outlook as Melanoma, TissueCypher Tests Gain Traction
Castle Biosciences Raises Outlook as Melanoma, TissueCypher Tests Gain Traction
CSTL

Castle Biosciences, Inc. (CSTL) Reports Q2 Loss, Tops Revenue Estimates
Castle Biosciences, Inc. (CSTL) Reports Q2 Loss, Tops Revenue Estimates
CSTL

Castle Biosciences Q2 Earnings Call Highlights
Castle Biosciences Q2 Earnings Call Highlights
CSTL

Castle Biosciences, Inc. (CSTL) Reports Q1 Loss, Beats Revenue Estimates
Castle Biosciences, Inc. (CSTL) Reports Q1 Loss, Beats Revenue Estimates
CSTL

Wall Street Analysts Predict an 85.15% Upside in Castle Biosciences (CSTL): Here's What You Should Know
Wall Street Analysts Predict an 85.15% Upside in Castle Biosciences (CSTL): Here's What You Should Know
CSTL

Castle Biosciences, Inc. (CSTL) Reports Q4 Loss, Beats Revenue Estimates
Castle Biosciences, Inc. (CSTL) Reports Q4 Loss, Beats Revenue Estimates
CSTL

Castle Biosciences, Inc. (CSTL) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
Castle Biosciences, Inc. (CSTL) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
CSTL

Castle Biosciences (CSTL) Loses 16.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Castle Biosciences (CSTL) Loses 16.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
CSTL
About Castle Biosciences, Inc. Common Stock
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Derek J. Maetzold | Founder, CEO, President & Director | 1962 |
| Mr. Frank Stokes | CFO & Treasurer | 1970 |
| Ms. Kristen M. Oelschlager R.N. | Chief Operating Officer | 1969 |
| Mr. Tobin W. Juvenal | Chief Commercial Officer | 1961 |
| Ms. Camilla Zuckero | Vice President of Investor Relations & Corporate Affairs | — |
| Ms. Keli Greenberg | Vice President of Human Resources | — |
| Dr. Matthew Goldberg M.D. | Senior Vice President of Medical | — |
| Ms. Trisha Poteet | Senior VP of Clinical Services & Manufacturing Operations | — |
| Dr. Hillary Caruso Ph.D. | Chief of Staff | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 48.53
- MACD 12/26/9
- 0.10
- EMA 9 of MACD
- 0.25
- MACD histogram
- -0.16
- SMA 50
- $34.30
- Price below SMA 50
- EMA 50
- $33.64
- Price above EMA 50
- SMA 200
- $28.24
- Price above SMA 200
- EMA 200
- $31.39
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
3 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $40.00
- Average
- $44.33
- High
- $52.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -7.2 | -12.3 | -2.2 | -15.0 | +13.7 | +13.3 | +8.7 | +6.3 | +5.4 | -2.7 |



